+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12362(UGT1A6 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12362(UGT1A6 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The UGT1A6 antibody is a crucial tool in studying the UDP-glucuronosyltransferase 1A6 (UGT1A6) enzyme, a member of the UGT superfamily involved in phase II drug metabolism. UGT1A6 catalyzes the glucuronidation of small phenolic compounds, neurotransmitters, and certain drugs, facilitating their excretion. This enzyme is predominantly expressed in the liver but is also found in extrahepatic tissues like the gastrointestinal tract and brain. Its activity impacts drug efficacy, toxicity, and interindividual variability in drug responses, influenced by genetic polymorphisms (e.g., UGT1A6*2 allele) and environmental factors.

UGT1A6 antibodies are designed to detect and quantify UGT1A6 protein levels in various samples, aiding research on enzyme expression patterns, tissue distribution, and regulatory mechanisms. They are widely used in techniques such as Western blotting, immunohistochemistry, and ELISA. These antibodies help explore UGT1A6's role in detoxification pathways, metabolic disorders, and diseases like cancer, where altered glucuronidation may affect carcinogen metabolism or drug resistance. Specificity validation is critical, as UGT isoforms share high sequence homology. Reliable UGT1A6 antibodies enable insights into personalized medicine, toxicology, and the development of therapies targeting metabolic enzymes.